The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND The epidemiology of mucormycosis in the era of modern diagnostics is relatively under-explored. OBJECTIVES To examine the contemporary epidemiology, clinical manifestations, diagnosis and causative pathogens of mucormycosis. DATA SOURCES Ovid MEDLINE and Ovid EMBASE from January 2000 to January 2017. STUDY ELIGIBILITY CRITERIA Published case reports/series of proven/probable mucormycosis. PARTICIPANTS Patients ≥18 years old. METHODS Patient characteristics, disease manifestations and causative pathogens were summarized descriptively. Categorical variables were assessed by chi-square test or Fischer's exact test, and continuous variables by the Wilcoxon-Mann-Whitney or Kruskal-Wallis test. Risk factors for the different clinical manifestations of mucormycosis were identified using multivariate logistic regression. RESULTS Initial database searches identified 3619 articles of which 600 (851 individual patient cases) were included in the final analysis. Diabetes mellitus was the commonest underlying condition (340/851, 40%) and was an independent risk for rhino-orbital-cerebral mucormycosis (odds ratio (OR) 2.49; 95% CI 1.77-3.54; p < 0.001). Underlying haematological malignancy was associated with disseminated infection (OR 3.86; 95% CI 1.78-8.37; p 0.001), whereas previous solid organ transplantation was associated with pulmonary (OR 3.19; 95% CI 1.50-6.82; p 0.003), gastrointestinal (OR 4.47; 95% CI 1.69-11.80; p 0.003), or disseminated (OR 4.20; 95% CI 1.68-10.46; p 0.002) mucormycosis. Eight genera (24 species) of Mucorales organisms were identified in 447/851 (53%) cases, of which Rhizopus spp. (213/447, 48%) was the most common. Compared with other genera, Rhizopus spp. was predominantly observed in patients with rhino-orbital-cerebral mucormycosis (75/213, 35% versus 34/234, 15%; p < 0.001). Death was reported in 389/851 (46%) patients. Mortality associated with Cunninghamella infections was significantly higher than those caused by other Mucorales (23/30, 71% versus 185/417, 44%; p < 0.001). However, Cunninghamella spp. were isolated primarily in patients with pulmonary (17/30, 57%) or disseminated disease (10/30, 33%). CONCLUSIONS Findings from the current review have helped ascertain the association between various manifestations of mucormycosis, their respective predisposing factors and causative organisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
Roden, M. M., Zaoutis, T. E., Buchanan, W. L., Knudsen, T. A., Sarkisova, T. A., Schaufele, R. L., Sein, M., Sein, T., Chiou, C. C., Chu, J. H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432579 · Cited by 3,044
Ribes, J. A., Vanover-Sams, C. L., & Baker, D. J. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.2.236 · Cited by 1,711
Morrison, A., Polisena, J., Husereau, D., Moulton, K., Clark, M., Fiander, M., Mierzwinski-Urban, M., Clifford, T., Hutton, B., & Rabb, D. (2012) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462312000086 · Cited by 1,257
Skiada, A., Pagano, L., Groll, A., Zimmerli, S., Dupont, B., Lagrou, K., Lass-Florl, C., Bouza, E., Klimko, N., Gaustad, P., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03456.x · Cited by 748
Kontoyiannis, D. P., Lionakis, M. S., Lewis, R. E., Chamilos, G., Healy, M., Perego, C., Safdar, A., Kantarjian, H., Champlin, R., Walsh, T. J., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/428780 · Cited by 674
The clinical case report: a review of its merits and limitations
Nissen, T., & Wynn, R. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-264 · Cited by 636
A Global Analysis of Mucormycosis in France: The RetroZygo Study (2005-2007)
Lanternier, F., Dannaoui, E., Morizot, G., Elie, C., Garcia-Hermoso, D., Huerre, M., Bitar, D., Dromer, F., Lortholary, O., & the French Mycosis Study Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir880 · Cited by 527
Cited by
Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India
Singh, A. K., Singh, R., Joshi, S. R., & Misra, A. (2021) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2021.05.019 · Cited by 1,102
Global Epidemiology of Mucormycosis
Prakash, H., & Chakrabarti, A. (2019) · Journal of Fungi · doi:10.3390/jof5010026 · Cited by 938
Epidemiology and Diagnosis of Mucormycosis: An Update
Skiada, A., Pavleas, I., & Drogari-Apiranthitou, M. (2020) · Journal of Fungi · doi:10.3390/jof6040265 · Cited by 687
COVID-19-associated fungal infections
Hoenigl, M., Seidel, D., Sprute, R., Cunha, C., Oliverio, M., Goldman, G. H., Ibrahim, A. S., & Carvalho, A. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01172-2 · Cited by 482
Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India
Patel, A., Agarwal, R., Rudramurthy, S. M., Shevkani, M., Xess, I., Sharma, R., Savio, J., Sethuraman, N., Madan, S., Shastri, P., et al. (2021) · Emerging Infectious Diseases · doi:10.3201/eid2709.210934 · Cited by 479
Epidemiology of Mucormycosis in India
Prakash, H., & Chakrabarti, A. (2021) · Microorganisms · doi:10.3390/microorganisms9030523 · Cited by 441
Mucormycosis with orbital compartment syndrome in a patient with COVID-19
Werthman-Ehrenreich, A. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2020.09.032 · Cited by 435
Sen, M., Honavar, S. G., Bansal, R., Sengupta, S., Rao, R., Kim, U., Sharma, M., Sachdev, M., Grover, A. K., Surve, A., et al. (2021) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1565_21 · Cited by 418
Patel, A., Kaur, H., Xess, I., Michael, J. S., Savio, J., Rudramurthy, S., Singh, R., Shastri, P., Umabala, P., Sardana, R., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.11.021 · Cited by 405
Chang, Z., & Heitman, J. (2019) · mBio · doi:10.1128/mbio.02579-19 · Cited by 202
“increase in the prevalence of predisposing factors (4, 5).”
BackgroundLet’s talk about sex characteristics—as a risk factor for invasive fungal diseases.
Egger, M., Hoenigl, M., Thompson, G. R., Carvalho, A., & Jenks, J. D. (2022) · Mycoses · doi:10.1111/myc.13449 · Cited by 82
Post-transcriptional control of antifungal resistance in human fungal pathogens
Sharma, C., & Kadosh, D. (2023) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2080527 · Cited by 6
“(Jeong et al. 2019).”
Metadata
- Authors
- Jeong, W., Keighley, C., Wolfe, R., Lee, W. L., Slavin, M. A., Kong, D. C. M., & Chen, S. C.-A.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 25
- Issue
- 1
- Pages
- 26-34
- ISSN
- 1198-743X (ISSN-L)
- OpenAlex
- W2883135211
- Cited by
- 1,082
- References
- 40
- FWCI
- 11.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.